The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

In a historic first, a therapy developed by Summit Therapeutics beat Merck blockbuster Keytruda in late-stage lung cancer ...

Investors were undoubtedly especially glad to see key insiders agree to buy more Summit Therapeutics stock. Together, co-CEOs ...